Skip to main content
. 2016 Jul;41(7):418–422.

Table 1.

Comparison of Brexpiprazole and Aripiprazole8,12

Brexpiprazole Aripiprazole
FDA-approved indications
  • Schizophrenia

  • Adjunctive for major depressive disorder

  • Acute agitation

  • Schizophrenia

  • Bipolar I disorder (acute mania or mixed episode)

  • Adjunctive for major depressive disorder

Predominant receptor binding 5-HT1A, D2, D3 partial agonist and 5-HT2A, 5-HT2B, 5-HT7, alpha1A, alpha1B, alpha1D, and alpha2C antagonist D2 and 5-HT1A partial agonist and 5-HT2A antagonist
Predominant metabolism CYP2D6 and CYP3A4 CYP2D6 and CYP3A4
Adverse events Akathisia, weight gain, constipation, fatigue, somnolence, headache, tremor, dizziness, dyspepsia, and extrapyramidal symptoms Akathisia, headache, weight gain, sedation, somnolence, dizziness, tremor, and extrapyramidal symptoms